Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDRESS+: Follow-up Trial of Efgartigimod PH20 SC in Pemphigus
2020-002917-16Phase 3Completed
- Sponsor
- argenx
- Start
- Aug 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa + hyaluronidase-qvfc in pemphigus vulgaris (PV) and pemphigus foliaceus (PF), sponsored by argenx. Primary endpoint: Incidence and severity of TEAEs, AESIs, and SAEs. Started Aug 2020; status: completed.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on 2020-002917-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002917-16.